Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series
- PMID: 30972617
- DOI: 10.1007/s12185-019-02638-6
Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series
Abstract
A proportion of patients with immune thrombocytopenic purpura are refractory to multiple therapies including thrombopoietin-receptor agonists (TPO-RA). We report 10 patients who did not respond to a TPO-RA until the addition of a glucocorticoid. These patients were previously treated with a median of 6 therapies. One patient elected to discontinue both medications despite persistent thrombocytopenia. The remaining 9 patients continued on the combination of prednisone (doses 5 mg every other day to 10 mg daily) and a TPO-RA. Combination therapy with low dose glucocorticoid and a TPO-RA may be an option for patients unresponsive to a TPO-RA alone.
Keywords: Autoimmune thrombocytopenia; Glucocorticoids; Immune thrombocytopenic purpura; Refractory; Thrombopoietin-receptor agonists.
Similar articles
-
Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.Am J Hematol. 2016 May;91(5):E293-5. doi: 10.1002/ajh.24341. Epub 2016 Apr 4. Am J Hematol. 2016. PMID: 26910388
-
Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.Hamostaseologie. 2019 Aug;39(3):272-278. doi: 10.1055/s-0038-1676129. Epub 2019 Jan 15. Hamostaseologie. 2019. PMID: 30646404 Review.
-
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.Br J Haematol. 2011 Oct;155(2):248-55. doi: 10.1111/j.1365-2141.2011.08845.x. Epub 2011 Sep 9. Br J Haematol. 2011. PMID: 21902682
-
Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.Ann Hematol. 2017 Mar;96(3):507-508. doi: 10.1007/s00277-016-2896-3. Epub 2016 Dec 15. Ann Hematol. 2017. PMID: 27975127 No abstract available.
-
Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.Blood Adv. 2019 Jun 25;3(12):1907-1915. doi: 10.1182/bloodadvances.2019000279. Blood Adv. 2019. PMID: 31239245 Free PMC article. Review.
Cited by
-
Sex differences in the associations of body size and body shape with platelets in the UK Biobank cohort.Biol Sex Differ. 2023 Feb 22;14(1):12. doi: 10.1186/s13293-023-00494-y. Biol Sex Differ. 2023. PMID: 36814334 Free PMC article.
-
Common-sense combination therapy in refractory immune thrombocytopaenia.Br J Haematol. 2023 Aug;202(4):728-730. doi: 10.1111/bjh.18919. Epub 2023 Jun 7. Br J Haematol. 2023. PMID: 37287116 Free PMC article. No abstract available.
-
[Chinese expert consensus on the clinical application of recombinant human thrombopoiein and thrombopoiein receptor agonist (2023)].Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):535-542. doi: 10.3760/cma.j.issn.0253-2727.2023.07.002. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37749031 Free PMC article. Chinese. No abstract available.
-
Targeting CCR5 with miltefosine as a therapeutic strategy for thrombocytopenia.iScience. 2025 Apr 8;28(5):112379. doi: 10.1016/j.isci.2025.112379. eCollection 2025 May 16. iScience. 2025. PMID: 40292315 Free PMC article.
-
Activating SRC/MAPK signaling via 5-HT1A receptor contributes to the effect of vilazodone on improving thrombocytopenia.Elife. 2024 Apr 4;13:RP94765. doi: 10.7554/eLife.94765. Elife. 2024. PMID: 38573820 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical